Abstract 2676
Background
Oncology nurses are responsible to provide their patients with the evidence-based care. Clinical guidelines or recommendations can be developed by scientific associations as a guide for performing evidence-based practice. These guidelines are often taken into consideration for the assessment of professional responsibility, as well as to guide the practice. The Italian Institute of Health identified the Italian Association of Cancer Nurses (AIIAO) among the scientific societies authorised to produce, adapt and implement guidelines. However, it is important to identify which areas of oncology nursing warrant an action to facilitate AIIAO in setting the agenda. A specific prerequisite for developing high-quality guidelines is incorporating nurses’ views into priority-setting. The aim of this study is to use a bottom-up approach to empirically investigate which areas of oncology nursing require higher priority in the definition of evidence-based recommendations.
Methods
This is a multi-phase study including a cross-sectional national survey. In order to develop the tool for the survey, a systematic search of the literature, a focus group, and content and face validity evaluation will be conducted.
Results
Seven areas were identified by the literature review to develop the survey: (a) fatigue; (b) pain; (c) sleep disorders; (d) secondary symptoms; (e) cognitive impairment resulting from cancer and its treatment; (f) chemotherapy-induced peripheral neuropathy; and (g) psychological distress. This research is still ongoing. A panel of researchers are operationalising the identified areas in the items for the national survey. Cancer nurses will be asked to rate the priority of each area for the implementation, adaptation and development of AIIAO clinical guidelines.
Conclusions
The results of this survey might raise awareness about oncology nurses’ opinions on which areas of clinical practice warrant an action. This will facilitate the associations and affiliated working groups in developing evidence-based recommendations. Moreover, a bottom-up mapping of the nurses’ priorities will inform the planning of AIIAO strategic activities targeted to strengthen cancer care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Italian Association of Cancer Nurses (AIIAO).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract